Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
Public ClinicalTrials.gov record NCT00033644. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus sargramostim in treating patients who have advanced, persistent, or recurrent cancer of the uterus.
Study identification
- NCT ID
- NCT00033644
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- sargramostim Biological
- cisplatin Drug
- dacarbazine Drug
- doxorubicin hydrochloride Drug
- mitomycin C Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2002 (Type not available)
- Primary completion
- Oct 2005 (Actual)
- Completion
- Not listed
- Last update posted
- Apr 11, 2013
Started 2002
United States locations
- U.S. sites
- 20
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Jonsson Comprehensive Cancer Center, UCLA | Los Angeles | California | 90095-1781 | — |
| University of Colorado Cancer Center | Denver | Colorado | 80010 | — |
| Walter Reed Army Medical Center | Washington D.C. | District of Columbia | 20307-5001 | — |
| Rush-Presbyterian-St. Luke's Medical Center | Chicago | Illinois | 60612-3864 | — |
| Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242-1009 | — |
| Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support | Bethesda | Maryland | 20892-1182 | — |
| Tuft-New England Medical Center | Boston | Massachusetts | 02111 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905-0001 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Cooper University Hospital | Camden | New Jersey | 08103-1489 | — |
| State University of New York Health Sciences Center - Stony Brook | Stony Brook | New York | 11794-8091 | — |
| Lineberger Comprehensive Cancer Center, UNC | Chapel Hill | North Carolina | 27599-7295 | — |
| Duke Comprehensive Cancer Center | Durham | North Carolina | 27710 | — |
| Comprehensive Cancer Center at Wake Forest University | Winston-Salem | North Carolina | 27157-1065 | — |
| Barrett Cancer Center | Cincinnati | Ohio | 45267-0526 | — |
| University of Oklahoma College of Medicine | Oklahoma City | Oklahoma | 73190 | — |
| Abington Memorial Hospital | Abington | Pennsylvania | 19001-3788 | — |
| University of Pennsylvania Cancer Center | Philadelphia | Pennsylvania | 19104-4283 | — |
| University of Texas Medical Branch | Galveston | Texas | 77555-0587 | — |
| Tacoma General Hospital | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00033644, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 11, 2013 · Synced Nov 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00033644 live on ClinicalTrials.gov.